Olvanil Reduces Subcutaneous Fat Accumulation and Lipogenic Gene Expression, Without Alleviating Hepatic Oxidative Stress or Histopathological Alterations in Mice with Metabolic Dysfunction-Associated Steatotic Liver Disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excess intrahepatic lipid accumulation due to lipid overflow and synthesis, as well as impaired lipid oxidation. Olvanil (OLV) is a nonpungent capsaicin analog that has previously been shown to have anti-obesity effects in diet-induced obesity models. Nevertheless, its effects on fatty liver remain unclear. In this study, we evaluated the potential of OLV to address lipid metabolic dysfunction and MASLD-related hepatic abnormalities. C57BL/6 mice were fed a high-fat/high-fructose diet for 24 weeks, with or without OLV (25 mg/kg/day) administered by oral gavage for the last 8 weeks. We primarily evaluated the effects of OLV on liver function markers and the hepatic expression of key genes involved in lipid metabolism to assess its potential in reducing MASLD progression. We confirmed that OLV promoted lipolysis in adipocytes and significantly reduced body weight gain and fat accumulation, particularly in subcutaneous adipose tissue. At the molecular level, we demonstrated that OLV reduced the expression of lipogenic genes ( ACC, FASN, SREBP-1c, and PPAR-γ ). However, we observed elevated serum alanine aminotransferase levels and increased interleukin-6 and thiobarbituric acid reactive substances levels in liver tissue. Moreover, histopathological alterations such as hepatic steatosis and lobular inflammation tended to be more pronounced in OLV-treated animals than in untreated MASLD animals. In conclusion, while OLV reduced subcutaneous adiposity and liver lipogenic gene expression, it did not improve hepatic oxidative stress or histopathological alterations in a murine MASLD model. Free fatty acid-mediated lipotoxicity may be present, exacerbating hepatic oxidative stress and inflammatory changes; therefore, further studies are needed to confirm the proposed metabolic pathway.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Food
Published
2026-10-29
DOI
https://doi.org/10.1177/1096620x261499871
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Olvanil Reduces Subcutaneous Fat Accumulation and Lipogenic Gene Expression, Without Alleviating Hepatic Oxidative Stress or Histopathological Alterations in Mice with Metabolic Dysfunction-Associated Steatotic Liver Disease

Edwin Estefan Reza-Zaldívar, Elda Cristina Villaseñor-Tapia, Alejandro Arturo Canales-Aguirre, Edgar Mendieta-Condado et al.
2 links
Journal of Medicinal Food
Liver Disease Diagnosis and Treatment
article

Olvanil Reduces Subcutaneous Fat Accumulation and Lipogenic Gene Expression, Without Alleviating Hepatic Oxidative Stress or Histopathological Alterations in Mice with Metabolic Dysfunction-Associated Steatotic Liver Disease

Edwin Estefan Reza-Zaldívar, Elda Cristina Villaseñor-Tapia, Alejandro Arturo Canales-Aguirre, Edgar Mendieta-Condado, Ana Laura Márquez-Aguirre, Jorge Alberto Rodríguez, David Alejandro Curiel-Pedraza
article en

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excess intrahepatic lipid accumulation due to lipid overflow and synthesis, as well as impaired lipid oxidation. Olvanil (OLV) is a nonpungent capsaicin analog that has previously been shown to have anti-obesity effects in diet-induced obesity models. Nevertheless, its effects on fatty liver remain unclear. In this study, we evaluated the potential of OLV to address lipid metabolic dysfunction and MASLD-related hepatic abnormalities. C57BL/6 mice were fed a high-fat/high-fructose diet for 24 weeks, with or without OLV (25 mg/kg/day) administered by oral gavage for the last 8 weeks. We primarily evaluated the effects of OLV on liver function markers and the hepatic expression of key genes involved in lipid metabolism to assess its potential in reducing MASLD progression. We confirmed that OLV promoted lipolysis in adipocytes and significantly reduced body weight gain and fat accumulation, particularly in subcutaneous adipose tissue. At the molecular level, we demonstrated that OLV reduced the expression of lipogenic genes ( ACC, FASN, SREBP-1c, and PPAR-γ ). However, we observed elevated serum alanine aminotransferase levels and increased interleukin-6 and thiobarbituric acid reactive substances levels in liver tissue. Moreover, histopathological alterations such as hepatic steatosis and lobular inflammation tended to be more pronounced in OLV-treated animals than in untreated MASLD animals. In conclusion, while OLV reduced subcutaneous adiposity and liver lipogenic gene expression, it did not improve hepatic oxidative stress or histopathological alterations in a murine MASLD model. Free fatty acid-mediated lipotoxicity may be present, exacerbating hepatic oxidative stress and inflammatory changes; therefore, further studies are needed to confirm the proposed metabolic pathway.

Journal of Medicinal Food
Secretaría de Salud de Jalisco (MX), Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco (MX), Tecnológico de Monterrey (MX)
Good health and well-being
Openalex Percentile: Top 12%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon